Emergence of molecular imaging of aortic aneurysm: Implications for risk stratification and management

Journal of Nuclear Cardiology

Volumn 21, Issue 2, 2014, Pages 251-267

  Golestani, Reza ^a,b   Sadeghi, Mehran M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Aneurysm; aorta; inflammation; molecular imaging; remodeling

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; NANOPARTICLE; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN RECEPTOR; VITRONECTIN RECEPTOR;

ABDOMINAL AORTA ANEURYSM; AGED; ANGIOGENESIS; ARTICLE; CASE REPORT; DRUG UPTAKE; DYSLIPIDEMIA; GENETICS; HEREDITY; HUMAN; IMAGING; INFLAMMATION; ISOTOPE LABELING; MALE; METABOLISM; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; STRATIFICATION; ULTRASOUND;

AORTIC ANEURYSM; BIOLOGICAL MARKERS; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR IMAGING; RISK ASSESSMENT;

EID: 84898832330     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-013-9845-5     Document Type: Article

References (116)

1. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2008. Natl Vital Stat Rep 2011;59:1-126.
2. Sterpetti AV, Schultz RD, Feldhaus RJ, Cheng SE, Peetz DJ Jr. Factors influencing enlargement rate of small abdominal aortic aneurysms. J Surg Res 1987;43:211-9.
3. U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: Recommendation statement. Ann Intern Med 2005;142:198-202.
4. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, et al. The aneurysm detection and management study screening program: Validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000;160:1425-30.
5. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, et al. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ 2004;329:1259.
6. Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms. J Vasc Surg 2012;56:565-71.
7. Olsson C, Thelin S, Stahle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: Increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation 2006;114:2611-8.
8. Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993;328:1167-72.
9. Cosford PA, Leng GC. Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2007;2:CD002945.
10. Lederle FA. Screening for AAA in the USA. Scand J Surg 2008;97:139-41.
11. Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, Sicard GA, et al. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: Executive summary. J Vasc Surg 2009;50:880-96.
12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-654.
13. Thompson S, Brown L, Sweeting M, Bown M, Kim L, Glover M, et al. Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: Implications for surveillance intervals and their cost-effectiveness. Health Technol Assess 2013;17:1-118.
14. RESCAN Collaborators, Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG. Surveillance intervals for small abdominal aortic aneurysms: A meta-analysis. JAMA 2013;309:806-13.
15. Powell JT, Brady AR, Brown LC, Forbes JF, Fowkes FGR, Greenhalgh RM, et al. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998;352:1649-55.
16. El-Hamamsy I, Yacoub MH. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol 2009;6:771-86.
17. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011;8:92-102.
18. Ruddy JM, Jones JA, Ikonomidis JS. Pathophysiology of thoracic aortic aneurysm (TAA): Is it not one uniform aorta? Role of embryologic origin. Prog Cardiovasc Dis 2013;56:68-73.
19. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006;26:987-94.
20. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of abdominal aortic aneurysm progression. Part 2: Inflammation. Nat Rev Cardiol 2009;6:543-52.
21. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.
22. Sakalihasan N, Van Damme H, Gomez P, Rigo P, Lapiere CM, Nusgens B, et al. Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 2002;23:431-6.
23. Kato K, Nishio A, Kato N, Usami H, Fujimaki T, Murohara T. Uptake of 18F-FDG in acute aortic dissection: A determinant of unfavorable outcome. J Nucl Med 2010;51:674-81.
24. Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC, Cullum I, et al. Vascular inflammation imaging with 18F-FDG PET/CT: When to image? J Nucl Med 2009;50:854-7.
25. Kotze CW, Menezes LJ, Endozo R, Groves AM, Ell PJ, Yusuf SW. Increased metabolic activity in abdominal aortic aneurysm detected by 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Eur J Vasc Endovasc Surg 2009;38:93-9.
26. Truijers M, Kurvers HA, Bredie SJ, Oyen WJ, Blankensteijn JD. In vivo imaging of abdominal aortic aneurysms: Increased FDG uptake suggests inflammation in the aneurysm wall. J Endovasc Ther 2008;15:462-7.
27. Kuehl H, Eggebrecht H, Boes T, Antoch G, Rosenbaum S, Ladd S, et al. Detection of inflammation in patients with acute aortic syndrome: Comparison of FDG-PET/CT imaging and serological markers of inflammation. Heart 2008;94:1472-7.
28. Kotze CW, Groves AM, Menezes LJ, Harvey R, Endozo R, Kayani IA, et al. What is the relationship between (1)F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nucl Med Mol Imaging 2011;38:1493-9.
29. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanning to the evaluation of abdominal aortic aneurysm. Semin Vasc Surg 2004;17:144-53.
30. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein HH, Krause BJ. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg 2008;48:417-23 discussion 24.
31. Blockmans D, Coudyzer W, Vanderschueren S, Stroobants S, Loeckx D, Heye S, et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology 2008;47:1179-84.
32. Reeps C, Pelisek J, Bundschuh RA, Gurdan M, Zimmermann A, Ockert S, et al. Imaging of acute and chronic aortic dissection by 18F-FDG PET/CT. J Nucl Med 2010;51:686-91.
33. Xu XY, Borghi A, Nchimi A, Leung J, Gomez P, Cheng Z, et al. High levels of 18F-FDG uptake in aortic aneurysm wall are associated with high wall stress. Eur J Vasc Endovasc Surg 2010;39:295-301.
34. Courtois A, Nusgens BV, Hustinx R, Namur G, Gomez P, Somja J, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med 2013;54:1740-7.
35. Hellmann DB, Grand DJ, Freischlag JA. Inflammatory abdominal aortic aneurysm. JAMA 2007;297:395-400.
36. Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, et al. Response to 'Laurberg JM, Olsen AK, Hansen SB, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: No FDG accumulation' [Atherosclerosis 2006]. Atherosclerosis 2007;192:453-4; author reply 1-2.
37. Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: Ready for prime time? J Am Coll Cardiol 2010;55:2527-35.
38. Tavakoli S, Zamora D, Ullevig S, Asmis R. Bioenergetic profiles diverge during macrophage polarization: Implications for the interpretation of 18F-FDG PET imaging of atherosclerosis. J Nucl Med 2013;54:1661-7.
39. Christen T, Sheikine Y, Rocha VZ, Hurwitz S, Goldfine AB, Di Carli M, et al. Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging. JACC Cardiovasc Imaging 2010;3:843-51.
40. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages implications for imaging atherosclerosis with (18)fluorine-labeled 2-deoxy-d-glucose positron emission tomography. J Am Coll Cardiol 2011;58:603-14.
41. Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Boyle RJ, Newman MJ, et al. Assessment of macrophage infiltration in a murine model of abdominal aortic aneurysm. J Magn Reson Imaging 2009;30:455-60.
42. Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol 2008;28:265-71.
43. Sadat U, Taviani V, Patterson AJ, Young VE, Graves MJ, Teng Z, et al. Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of abdominal aortic aneurysms: A feasibility study. Eur J Vasc Endovasc Surg 2011;41:167-74.
44. Nchimi A, Defawe O, Brisbois D, Broussaud TK, Defraigne JO, Magotteaux P, et al. MR imaging of iron phagocytosis in intraluminal thrombi of abdominal aortic aneurysms in humans. Radiology 2010;254:973-81.
45. Richards JM, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: A pilot study. Circ Cardiovasc Imaging 2011;4:274-81.
46. Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: Still "rusty?". J Am Coll Cardiol 2009;53:2051-2.
47. Stoll G, Bendszus M. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience 2009;158:1151-60.
48. Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009;29:1001-8.
49. Yao Y, Wang Y, Zhang Y, Li Y, Sheng Z, Wen S, et al. In vivo imaging of macrophages during the early-stages of abdominal aortic aneurysm using high resolution MRI in ApoE mice. PloS One 2012;7:e33523.
50. Kooi ME, Cappendijk VC, Cleutjens KB, Kessels AG, Kitslaar PJ, Borgers M, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453-8.
51. Nahrendorf M, Keliher E, Marinelli B, Leuschner F, Robbins CS, Gerszten RE, et al. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol 2011;31:750-7.
52. Schafers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schafers KP, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004;109:2554-9.
53. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: Visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55-62.
54. Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: Resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008;52:1847-57.
55. Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 2008;28:425-32.
56. Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008;118:1953-60.
57. Amirbekian V, Aguinaldo JG, Amirbekian S, Hyafil F, Vucic E, Sirol M, et al. Atherosclerosis and matrix metalloproteinases: Experimental molecular MR imaging in vivo. Radiology 2009;251:429-38.
58. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002;105:2766-71.
59. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol 2009;29:1444-51.
60. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011;278:28-45.
61. Schafers M, Schober O, Hermann S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. J Nucl Med 2010;51:663-6.
62. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7:743-8.
63. Suter MJ, Nadkarni SK, Weisz G, Tanaka A, Jaffer FA, Bouma BE, et al. Intravascular optical imaging technology for investigating the coronary artery. JACC Cardiovasc Imaging 2011;4:1022-39.
64. Kaijzel EL, van Heijningen PM, Wielopolski PA, Vermeij M, Koning GA, van Cappellen WA, et al. Multimodality imaging reveals a gradual increase in matrix metalloproteinase activity at aneurysmal lesions in live fibulin-4 mice. Circ Cardiovasc Imaging 2010;3:567-77.
65. Sheth RA, Maricevich M, Mahmood U. In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis 2010;212:181-7.
66. Bazeli R, Coutard M, Duport BD, Lancelot E, Corot C, Laissy JP, et al. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol 2010;45:662-8.
67. Ouimet T, Lancelot E, Hyafil F, Rienzo M, Deux F, Lemaitre M, et al. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Mol Pharm 2012;9:850-61.
68. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005;112:3157-67.
69. Razavian M, Zhang J, Nie L, Tavakoli S, Razavian N, Dobrucki LW, et al. Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nucl Med 2010;51:1107-15.
70. Sanders HM, Iafisco M, Pouget EM, Bomans PH, Nudelman F, Falini G, et al. The binding of CNA35 contrast agents to collagen fibrils. Chem Commun 2011;47:1503-5.
71. Klink A, Heynens J, Herranz B, Lobatto ME, Arias T, Sanders HM, et al. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol 2011;58:2522-30.
72. Makowski M, Wiethoff A, Ebersberger U, Blume U, Warley A, Jansen C, et al. Molecular assessment of aortic aneurysm wall integrity using an elastin-specific MR imaging probe. J Cardiovasc Magn Reson 2013;15:1-3.
73. von Bary C, Makowski M, Preissel A, Keithahn A, Warley A, Spuentrup E, et al. MRI of coronary wall remodeling in a swine model of coronary injury using an elastin-binding contrast agent. Circ Cardiovasc Imaging 2011;4:147-55.
74. Makowski MR, Wiethoff AJ, Blume U, Cuello F, Warley A, Jansen CH, et al. Assessment of atherosclerotic plaque burden with an elastin-specific magnetic resonance contrast agent. Nat Med 2011;17:383-8.
75. Holmes DR, Liao S, Parks WC, Thompson RW. Medial neovascularization in abdominal aortic aneurysms: A histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995;21:761-71 discussion 71-2.
76. Paik DC, Fu C, Bhattacharya J, Tilson MD. Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004;36:524-33.
77. Thompson MM, Jones L, Nasim A, Sayers RD, Bell PR. Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996;11:464-9.
78. Scott DJ, Allen CJ, Honstvet CA, Hanby AM, Hammond C, Johnson AB, et al. Lymphangiogenesis in abdominal aortic aneurysm. Br J Surg 2013;100:895-903.
79. Choke E, Thompson MM, Dawson J, Wilson WR, Sayed S, Loftus IM, et al. Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol 2006;26:2077-82.
80. Jaffer FA, Sosnovik DE, Nahrendorf M, Weissleder R. Molecular imaging of myocardial infarction. J Mol Cell Cardiol 2006;41:921-33.
81. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49(Suppl 2):113S-28S.
82. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 2010;7:38-47.
83. Dobrucki LW, de Muinck ED, Lindner JR, Sinusas AJ. Approaches to multimodality imaging of angiogenesis. J Nucl Med 2010;51(Suppl 1):66S-79S.
84. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001;188:359-68.
85. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res 1998;83:832-40.
86. Zhang J, Silva T, Yarovinsky T, Manes TD, Tavakoli S, Nie L, et al. VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res 2010;107:408-17.
87. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001;97:785-91.
88. Tedesco MM, Terashima M, Blankenberg FG, Levashova Z, Spin JM, Backer MV, et al. Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol 2009;29:1452-7.
89. Zhang J, Razavian M, Tavakoli S, Nie L, Tellides G, Backer JM, et al. Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis. Arterioscler Thromb Vasc Biol 2012;32:1849-55.
90. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell 2002;110:673-87.
91. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: The end game. Nat Rev Mol Cell Biol 2010;11:288-300.
92. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci 2009;14:887-99.
93. Danhier F, Le Breton A, Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012;9:2961-73.
94. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 1995;77:1129-35.
95. Huang S, Endo RI, Nemerow GR. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery. J Virol 1995;69:2257-63.
96. Sadeghi MM, Krassilnikova S, Zhang J, Gharaei AA, Fassaei HR, Esmailzadeh L, et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation 2004;110:84-90.
97. Razavian M, Marfatia R, Mongue-Din H, Tavakoli S, Sinusas AJ, Zhang J, et al. Integrin-targeted imaging of inflammation in vascular remodeling. Arterioscler Thromb Vasc Biol 2011;31:2820-6.
98. Kitagawa T, Kosuge H, Chang E, James ML, Yamamoto T, Shen B, et al. Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by 18F-FPPRGD2 positron emission tomography. Circ Cardiovasc Imaging 2013;6:950-6.
99. Gillis E, Van Laer L, Loeys BL. Genetics of thoracic aortic aneurysm: At the crossroad of transforming growth factor-beta signaling and vascular smooth muscle cell contractility. Circ Res 2013;113:327-40.
100. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010;121:e266-369.
101. Kuivaniemi H, Shibamura H, Arthur C, Berguer R, Cole CW, Juvonen T, et al. Familial abdominal aortic aneurysms: Collection of 233 multiplex families. J Vasc Surg 2003;37:340-5.
102. Larsson E, Granath F, Swedenborg J, Hultgren R. A population-based case-control study of the familial risk of abdominal aortic aneurysm. J Vasc Surg 2009;49:47-50 discussion 1.
103. Golledge J, Kuivaniemi H. Genetics of abdominal aortic aneurysm. Curr Opin Cardiol 2013;28:290-6.
104. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008;118:2382-92.
105. Dawson J, Cockerill GW, Choke E, Belli AM, Loftus I, Thompson MM. Aortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg 2007;45:350-6.
106. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001;103:2260-5.
107. Norman P, Spencer CA, Lawrence-Brown MM, Jamrozik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 2004;110:862-6.
108. Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: A meta-analysis. Interact Cardiovasc Thorac Surg 2009;9:437-40.
109. Wilson WR, Anderton M, Choke EC, Dawson J, Loftus IM, Thompson MM. Elevated plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 2008;35:580-4.
110. Malkawi AH, Hinchliffe RJ, Xu Y, Holt PJ, Loftus IM, Thompson MM. Patient-specific biomechanical profiling in abdominal aortic aneurysm development and rupture. J Vasc Surg 2010;52:480-8.
111. Pappu S, Dardik A, Tagare H, Gusberg RJ. Beyond fusiform and saccular: A novel quantitative tortuosity index may help classify aneurysm shape and predict aneurysm rupture potential. Ann Vasc Surg 2008;22:88-97.
112. Fillinger MF, Raghavan ML, Marra SP, Cronenwett JL, Kennedy FE. In vivo analysis of mechanical wall stress and abdominal aortic aneurysm rupture risk. J Vasc Surg 2002;36:589-97.
113. Vande Geest JP, Di Martino ES, Bohra A, Makaroun MS, Vorp DA. A biomechanics-based rupture potential index for abdominal aortic aneurysm risk assessment: Demonstrative application. Ann N Y Acad Sci 2006;1085:11-21.
114. Trollope A, Moxon JV, Moran CS, Golledge J. Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol 2011;20:114-23.
115. Ouriel K. The PIVOTAL study: A randomized comparison of endovascular repair versus surveillance in patients with smaller abdominal aortic aneurysms. J Vasc Surg 2009;49:266-9.
116. Thompson SG, Ashton HA, Gao L, Scott RA, Multicentre Aneurysm Screening Study G. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009;338:2307.